Recommendation of the President – Pemazyre (pemigatinib)
On 9 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 144/2025 on the reimbursement of the medicinal product Pemazyre (pemigatinib) under the B.5 drug program. “Treatment of patients with hepatocellular carcinoma (ICD-10 C22.0) or bile duct cancer (ICD-10: C22.1, C23, C24.0, C24.1, C24.8, C24.9)”